ATAIATAI Life Sciences N.V.

Nasdaq atai.life


$ 1.22 $ -0.03 (-2.4 %)    

Friday, 16-Aug-2024 15:59:28 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 1.22
$ 1.21 x 5,400
-- x --
-- - --
$ 1.03 - $ 2.85
814,985
na
195.67M
$ 1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 atais-dmt-depression-drug-shows-promise-prepares-for-phase-ii-trial-and-future-collaboration-with-pharma-giant

Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targe...

 hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

 cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

 atai-life-sciences-announced-an-update-on-beckley-psytechs-phase-12a-trial-of-ele-101-for-major-depressive-disorder-with-initial-results-from-phase-1-and-the-dosing-of-the-first-patients-in-the-phase-2a-part-of-the-study

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in...

 psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

 whats-going-on-with-mindmed-and-psychedelic-stocks

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...

 hc-wainwright--co-reiterates-buy-on-atai-life-sciences-maintains-15-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...

 atai-life-sciences-q1-eps-017-beats-018-estimate-cash-1887m

ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...

 atai-life-sciences-announces-the-publication-of-beckley-psytechs-phase-1-study-of-bpl-003-in-the-journal-of-psychopharmacology

atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to tr...

 cantor-fitzgerald-reiterates-overweight-on-atai-life-sciences

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.

 why-ulta-beauty-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...

 signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

 maxim-group-upgrades-atai-life-sciences-to-buy-announces-6-price-target

Maxim Group analyst Jason McCarthy upgrades ATAI Life Sciences (NASDAQ:ATAI) from Hold to Buy and announces $6 price target.

 hc-wainwright--co-maintains-buy-on-atai-life-sciences-lowers-price-target-to-15

HC Wainwright & Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and lowers the price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION